|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5549507||1556726||2017||5 صفحه PDF||سفارش دهید||دانلود کنید|
At the conclusion of all drug research is the 'approval of the (new) drug'. Therefore, for scientists, it's unavoidable to think about the process of regulation. First, keep in mind that all regulators are (very) conservative. All regulators have learned the lesson: avoid pharmacovigilance cases. Don't take risks; it will infringe on your career. Non-approval is the best way to avoid failures. To be frank, there were and are several unacceptable combinations on the market. If new ideas like 'synergy' come up, 'slow motion' is the state-of-the-art response among regulators. But, maybe there's light at the end of the tunnel.
Journal: Synergy - Volume 4, June 2017, Pages 8-12